Risk Factor Profiles in Patients with Different Clinical Manifestations of Venous Thromboembolism: A Focus on the Factor V Leiden Mutation

Summary

Background. Patients with venous thromboembolic disease may present with different clinical manifestations. Factor V Leiden mutation leading to resistance to activated protein C is associated with a sevenfold increased risk for presenting with deep-vein thrombosis. It is not yet established whether carriers of the mutation have a similarly increased risk for manifesting with pulmonary embolism.

Methods. From an Anticoagulation Clinic monitoring coumarin therapy, a consecutive series of patients with a first thromboembolic event (objectively proven by current radiological methods) were enrolled. All patients were interviewed and blood was drawn for geno-typing. From the hospital charts and the personal interview, information was obtained on acquired risk factors and the signs and symptoms on hospital admission.

Results. 45 patients presented with symptoms of pulmonary embolism only, 211 had only symptoms of deep-vein thrombosis whereas 23 had clinical features of both. In about half of the patients acquired risk factors for venous thromboembolism were present which did not differ between the three groups of patients. Recent surgery had been performed more often in patients presenting with pulmonary embolism than in other patients (33.3% vs. 18.5%, p <0,05). Factor V Leiden was present in 9% of the patients presenting with pulmonary embolism (relative risk: 3.3 95% Cl: 1.0-10.6) and 17% of the patients presenting with deep-vein thrombosis (relative risk: 6.9 95% Cl: 3.6-12.8). The prevalence of factor V Leiden was intermediate in patients with both clinical characteristics.

Conclusion. These data suggest that patients with venous thromboembolism have different clinical presentation depending on the risk factor profile. Factor V Leiden may preferentially lead to manifest deep-vein thrombosis. Differences in structure of venous thrombi could underlie differences in embolic tendency.

• References

• 1 Weinmann EE, Salzman EW. Deep- vein thrombosis. N Engl J Med 1994; 331: 630-641
• 2 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation associated with resistance to activated protein C. Nature 1994; 369: 64-67
• 3 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
• 4 Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thromboembolism due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-1506
• 5 Loeliger EA, van Dijk- Wierda CA, van den Besselaar AMHP, Broekmans AW, Roos J. Anticoagulant therapy and the risk of bleeding; organizational infrastructure. In: Meade TW. ed. Anticoagulants and myocardial infarction; a reappraisal. Chicester: John Wiley and sons; 1984: 157
• 6 Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-1508
• 7 Salzman EW, Hirsh J. The epidemiology, pathogenesis, and natural history of venous thrombosis. In: Hemostasis and Thrombosis: basic principles and practice Colman RW, Hirsh J, Marder VJ, Salzman EW. eds. 3rd ed Philadelphia: J B Lippincott; 1994: 1275-1296
• 8 Monreal M, Ruiz J, Olazabal A, Arias A, Roca J. Deep venous thrombosis and the risk of pulmonary embolism. Chest 1992; 102: 677-681
• 9 Moser KM, Le Moine JR. Is embolic risk conditioned by location of deep venous thrombosis?. Ann Int Med 1981; 94: 439-444
• 10 Philbrick JT, Becker DM. Calf deep venous thrombosis: a wolf in sheep’s clothing?. Arch Intern Med 1988; 148: 2131-2138
• 11 Desmarais S, de Moerloose P, Reber G, Minazio A, Bounameaux H. Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet 1996; 347: 1374-1375
• 12 Hull RD, Hirsh J, Carter CJ, Jay RM, Dodd PE, Ockelford PA, Coates G, Gill GJ, Turpie AG, Doyle DJ, Buller HR, Raskob GE. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Int Med 1983; 98: 891-899
• 13 Quinn DA, Thompson T, Terrin ML, Thrall JH, Athanasoulis CA, McKusick KA, Stein PD, Hales CA. A prospective investigation of pulmonary embolism in women and men. JAMA 1992; 268: 1689-1696
• 14 Hull RD, Hirsh J, Carter CJ, Raskob GE, Gill GJ, Jay RM, Leclerc JR, David M, Coates G. Diagnostic value of ventilation- perfusion lung scanning in patients with suspected pulmonary embolism. Chest 1985; 88: 819-828
• 15 Dahlbäck B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995; 85: 607-614
• 16 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer ML, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thromboembolism in apparently healthy men. N Engl J Med 1995; 332: 912-917
• 17 Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral- contraceptive users who are carrier of factor V Leiden mutation. Lancet 1994; 344: 1453-1457